MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2PRNewsWire • 11/20/23
MIRA Pharmaceuticals Shows its Prescription Pill More Palatable and Potent Than PotPRNewsWire • 09/18/23
MIRA Pharmaceuticals and MZ Group Partner to Strengthen Investor Relations and Shareholder Communication EffortsPRNewsWire • 09/05/23
MIRA Pharmaceuticals to Participate in 6th Annual Cannabinoid-Derived Drug Development SummitPRNewsWire • 08/31/23
MIRA Pharmaceuticals to Host Virtual Roadshow Webinar on Monday, September 11, 2023 at 1:00 p.m. Eastern TimePRNewsWire • 08/29/23
MIRA Pharmaceuticals, Inc. Discusses Potential of Revolutionary THC Analog Drug, MIRA1a, with The Stock Day PodcastAccesswire • 08/09/23
MIRA Pharmaceuticals to Ring the Nasdaq Opening Bell on Wednesday, August 9, 2023PRNewsWire • 08/09/23
MIRA Pharmaceuticals, Inc. Announces Closing of $8.9 Million Initial Public OfferingPRNewsWire • 08/07/23
MIRA Pharmaceuticals, Inc. Announces Pricing of $8.9 Million Initial Public Offering and Nasdaq ListingPRNewsWire • 08/02/23